Aska Pharmaceutical Co
Aska Pharmaceutical Co., Ltd., commonly referred to as Aska Pharma, is a prominent player in the pharmaceutical industry, headquartered in Japan (JP). Established in 1941, the company has made significant strides in developing innovative healthcare solutions, particularly in the fields of prescription pharmaceuticals and over-the-counter products. With a strong operational presence in Asia and beyond, Aska Pharma focuses on therapeutic areas such as cardiovascular, oncology, and infectious diseases. Their core offerings include unique formulations and advanced drug delivery systems that set them apart in a competitive market. Recognised for their commitment to quality and research, Aska Pharmaceutical has achieved notable milestones, including strategic partnerships and a robust pipeline of new drugs. Their dedication to improving patient outcomes solidifies their position as a trusted name in the global pharmaceutical landscape.
DitchCarbon Score
How does Aska Pharmaceutical Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aska Pharmaceutical Co's score of 18 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aska Pharmaceutical Co's reported carbon emissions
Aska Pharmaceutical Co, headquartered in Japan, reported its carbon emissions for the year 2022, totalling approximately 6,687,000 kg CO2e for Scope 1 and about 4,093,000 kg CO2e for Scope 2. This marks a reduction from 2021, where emissions were approximately 7,209,000 kg CO2e for Scope 1 and around 5,042,000 kg CO2e for Scope 2. In 2020, the company recorded total emissions of about 13,215,000 kg CO2e, with Scope 1 emissions at approximately 7,443,000 kg CO2e and Scope 2 at about 5,771,000 kg CO2e. Despite these reductions, Aska Pharmaceutical Co has not set specific science-based targets (SBTi) or documented reduction initiatives. The company does not disclose any Scope 3 emissions data, which typically includes indirect emissions from the supply chain and product use. Overall, Aska Pharmaceutical Co's commitment to reducing its carbon footprint is evident through its decreasing emissions over the past few years, although further transparency regarding future climate commitments and targets would enhance its sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 7,443,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 5,771,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aska Pharmaceutical Co is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
